Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory) that have been previously treated with brentuximab vedotin or checkpoint inhibitors. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving brentuximab vedotin and nivolumab in combination may be an effective treatment in patients with relapsed or refractory classic Hodgkin lymphoma previously treated with brentuximab vedotin or checkpoint inhibitors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem klasycznego chłoniaka Hodgkina
- •Wiek 12 lat lub więcej
- •Poprzednie leczenie: grupa A - jeden schemat zawierający brentuximab vedotin, bez prior inhibitorów punktu kontrolnego; grupa B - jeden schemat z inhibitorem punktu kontrolnego (nivolumab lub pembrolizumab), bez prior brentuximabu
- •Obecna mierzalna choroba - guz lub powiększone węzły chłonne większe niż 1,5 cm
- •Liczba neutrofili co najmniej 750, liczba płytek co najmniej 50 000
- •Prawidłowe wartości nerek i wątroby
- •Wyleczenie wszystkich wcześniejszych skutków ubocznych poprzednich leków do stopnia łagodnego
- •Brak poprzedniego przeszczepu szpiku kostnego
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- September 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Emory University Hospital/Winship Cancer Institute
Atlanta, United States
Emory Saint Joseph's Hospital
Atlanta, United States
Trial contact
Kristie A. Blum
Blair Dykeman
Kristie Blum
PRINCIPAL_INVESTIGATOR
Marcela Algave, CRN
Jason T Romancik, MD
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.